Multiple Myeloma Management: Addressing Disparities in Care
Before closing out their review on the management of multiple myeloma, panelists consider disparities in care and share how these barriers are being addressed.
Future Directions: Novel Targeted Therapies in Multiple Myeloma
A comprehensive review of novel therapy being investigated in the setting of relapsed/refractory multiple myeloma to expand the bispecific antibody and CAR T-cell therapy armamentarium.
Practical Factors in Selecting Therapy for Relapsed/Refractory MM
Shared insight on key factors that determine the best selection of therapy in patients with relapsed/refractory multiple myeloma, with a focus on bispecific antibodies and CAR T-cell therapy.
Patient Case 3: A 65-Year-Old Woman With Relapsed Multiple Myeloma
After reviewing their third patient case, expert hematologist-oncologists highlight the treatment armamentarium for relapsed/refractory multiple myeloma.
Treating High-Risk Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Before closing out their module on transplant-ineligible newly diagnosed multiple myeloma, panelists reflect on best treatment practices in the setting of high-risk disease.
Transplant-Ineligible NDMM: Optimizing Selection and Duration of Therapy
Practical perspectives on the optimal selection of therapy for transplant-ineligible NDMM, followed by considerations for duration of therapy and dosing.
Induction Therapy Options for Patients With Transplant-Ineligible NDMM
Expert perspectives on cornerstone induction therapy regimens used in patients with transplant-ineligible newly diagnosed multiple myeloma.
Patient Case 2: A 79-Year-Old Woman With Transplant-Ineligible NDMM
Switching their attention to the transplant-ineligible setting of newly diagnosed multiple myeloma, panelists center discussion around their second patient case.
Post-Transplant Therapy in NDMM: Consolidation and Maintenance Therapy
Expert hematologist-oncologists consider the role of maintenance and consolidation following the completion of transplant in patients with newly diagnosed multiple myeloma.
What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
A brief review of the role of transplant in patients with newly diagnosed multiple myeloma and how it can be best coupled with systemic treatment.
Induction Regimens in Transplant-Eligible NDMM: Clinical Trial Data
Comprehensive insight on mainstay induction therapy options for patients with transplant-eligible newly diagnosed multiple myeloma in the context of recent clinical studies.
Patient Case 1: A 54-Year-Old Woman With Transplant-Eligible NDMM
Opening their discussion on the first patient case, expert panelists review the management of transplant-eligible newly diagnosed multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512